• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Parylene Coatings for Medical Device Technologies

    The Big Shift: Nearshoring Trends in Medtech Manufacturing

    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    BD Recalls Intraosseous Products Over Multiple Issues

    Rapid Medical Expands U.S. Portfolio

    MMS Holdings Partners With Lindsay Goldberg

    ENDRA Life Sciences Issued 28th Patent

    Levita Magnetics Closes $26M Series C
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Parylene Coatings for Medical Device Technologies

    The Big Shift: Nearshoring Trends in Medtech Manufacturing

    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Cooling and Melting the Pain Away

    What Are the Fundamentals of Go-To-Market Strategy in Medical Devices?

    Minding the Gap: How Harmonizing Quality Systems Pays Off

    Building Strong Partnerships Between Medtech and Surgeon-Learning Platforms

    Four Key Considerations for OEMs Transferring a Product Program
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Concise Engineering

    Trademark Plastics Inc.

    JBC Technologies

    Cirtec Medical

    Fusion Biotec Inc.
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Medical Computing: COM Express Processes Real-Time Data at the Edge

    The Importance of Building Successful Supplier Relationships

    The Benefits of Outsourcing Innovation in Medtech Manufacturing

    Patching Healthcare Cybersecurity Risks in the Internet of Medical Things

    Leveraging Open Healthcare Data Standards to Improve Medical Device Manufacturing
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Concise Engineering

    Trademark Plastics Inc.

    JBC Technologies

    Cirtec Medical

    Fusion Biotec Inc.
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Breaking News

    PAVmed Subsidiary Lucid Diagnostics Launches Medical Advisory Board

    Company also appoints chief medical officer.

    PAVmed Subsidiary Lucid Diagnostics Launches Medical Advisory Board
    Related CONTENT
    • Fist Assist Devices Forms Global Medical Advisory Board
    • A New, Tailored Review Framework for Artificial Intelligence-Based Devices
    • FDA to Modernize Mammography Services and Improve Their Quality
    • Medtronic Launches MedTech Innovation Accelerator in Shanghai
    • FDA Warns J&J and Sientra for Breast Implant Compliance Failure
    Globe Newswire04.12.19
    PAVmed Inc. subsidiary Lucid Diagnostics Inc. (Lucid), has launched a medical advisory board (MAB) consisting of internationally renowned experts in gastroesophageal reflux disease (GERD), Barrett’s Esophagus (BE) and esophageal cancer and has appointed veteran life sciences industry executive David Wurtman, M.D., MBA, as its chief medical officer.
     
    The Lucid Medical Advisory Board members include:
    • Chairman Nicholas J. Shaheen, M.D., MPH, a professor of Medicine and Epidemiology at the University of North Carolina School of Medicine and University of North Carolina School of Public Health. He is chief of the Division of Gastroenterology and Hepatology UNC HealthCare, Chapel Hill, N.C. Shaheen also is director of the American College of Gastroentrology Institute for Clinical Research and Education.
    • Ambitabh Chak, M.D., a professor of Medicine at Case Western Reserve University School of Medicine. Chak is director of the Advanced Technology & Innovation Center of Excellence at University Hospitals Cleveland Medical Center, Division of Gastroenterology, in Cleveland, Ohio.
    • Gary W. Falk, M.D., MS, a professor of Medicine at the University of Pennsylvania Perelman School of Medicine. He also is clinical co-director, Joint Center for Digestive, Liver and Pancreatic Medicine;  co-director, Esophagology and Swallowing Center, Hospital of the University of Pennsylvania (Philadelphia); and past president of the American Society of Gastrointestinal Endoscopy.
    • Anthony Infantolino, M.D., a professor of Medicine at Thomas Jefferson University Sidney Kimmel Medical College. He also is director, Barrett's Esophagus Treatment Center; director, Endoscopic Ultrasound Unit; and co-director, Jefferson GI Bleeding Center, Thomas Jefferson University Hospital in Philadelphia, Pa. 
    • Prateek Sharma, M.D., a professor of Medicine at the University of Kansas School of Medicine. He also is director, Gastroenterology Fellowship Program; section chief, Veterans Affairs Medical Center in Kansas City, Mo.; and vice president, The International Society for Diseases of the Esophagus.
    • Michael S. Smith, M.D., MBA, an associate professor of Medicine at the Icahn School of Medicine at Mount Sinai. He also is chief of Gastroenterology and Hepatology at Mount Sinai West and Mount Sinai St. Luke's Hospitals in New York, N.Y.
    “I could not be more pleased to welcome such a prominent group of experts from prestigious institutions to the Lucid team,” said Lishan Aklog, M.D., PAVmed’s chairman and CEO and Lucid’s executive chairman. “The collective wisdom and experience of our MAB is absolutely remarkable. We look forward to tapping into this wisdom and experience to advance our regulatory and commercial strategy for the groundbreaking EsoCheck technology. Their specific expertise and experience in developing the current published society guidelines on the management of BE will be particularly helpful in these efforts.”

    Lucid MAB members have led the development of published guidelines on the management of Barrett’s Esophagus sanctioned by both major gastroenterology societies. Drs. Shaheen and Falk are lead authors of the current American College of Gastroenterology (ACG) guidelines on the Diagnosis and Management of Barrett’s Esophagus. Drs. Sharma and Shaheen are authors of the current American Gastroenterological Association Technical Review on the Management of Barrett's Esophagus.
     
    Lucid MAB members are co-founders, investigators and participants of all of the major clinical and research initiatives in the field of Barrett’s Esophagus including the National Cancer Institute’s (NCI) Barrett’s Esophagus Translational Research Network (BETRNet), GI Specialized Program of Research Excellence (GI SPORE) Centers, the Early Detection Research Network (EDRN), Barrett’s Esophageal and Adenocarcinoma Consortium (BEACON), and the Familial Barrett’s Esophagus Consortium (FBEC). Dr. Chak is an EsoCheck co-inventor and principal investigator of the ongoing National Institutes of Health-funded clinical trial of EsoCheck which includes Dr. Shaheen and his team.
     
    Lucid MAB members also serve on the editorial boards of the major gastroenterology journals including Gastroenterology, the American Journal of Gastroenterology, Clinical Gastroenterology and Hepatology, Gastrointestinal Endoscopy, and the Journal of Clinical Gastroenterology. They have collectively published hundreds of peer reviewed journal articles and served as lead editor and co-author of the definitive textbook, "Barrett’s Esophagus and Esophageal Adenocarcinoma."
     
    “I am honored to join my esteemed colleagues on Lucid Diagnostics’ Medical Advisory Board and to serve as its chair as it develops and executes its long-term clinical and regulatory plan for its EsoCheck technology,” said Dr. Shaheen. “I have spent my career seeking to improve the care of patients with GERD/Barrett’s Esophagus and to prevent deaths from esophageal cancer. I have actively participated in the development of key advances in this field and am particularly excited about the potential for the EsoCheck technology to save lives through the early detection of Barrett’s Esophagus.”
     
    Wurtman, joins PAVmed as its executive vice president, Strategic Projects and Lucid’s chief medical officer. Dr. Wurtman is a veteran life sciences industry executive who has held leadership roles in corporate development, business development and licensing, marketing, product development, and medical affairs for over two decades.
     
    He most recently served as president, CEO, and co-founder of Lyric Pharmaceuticals, which sought to develop novel therapeutics to improve the care of critically ill and hospitalized patients, including the treatment of enteral feeding intolerance in the intensive care unit. Dr. Wurtman led his team in completing a definitive international multi-center Phase 2 trial of ulimorelin, an IV ghrelin agonist. Prior to co-founding Lyric, he served as vice president of Medical Affairs and Product Development at Kineta Inc., a clinical stage biotechnology company, and maintained a successful practice as an independent corporate and product development consultant. Dr. Wurtman has held senior positions at Protein Design Labs (now PDL Biopharma), Eos Biotechnology Inc., and Genzyme Corporation (now Sanofi Genzyme), and worked in the pharmaceutical analyst group at SG Cowen (now Cowen Inc.). He has executed numerous licensing and partnering transactions and capital raises including a $33.8 million funding round for Lyric.

    “Dr. Wurtman brings an enormous amount of executive experience in the development and execution of clinical and regulatory strategy, including sophisticated clinical trials, to his role as Lucid’s chief medical officer,” said Dr. Aklog. “I am excited that he will lead EsoCheck’s clinical and regulatory efforts. He will apply his expertise to the design and execution of Lucid-sponsored clinical studies of EsoCheck, in close collaboration with our MAB and former FDA officials retained through a leading regulatory consulting firm with the ultimate goal of securing a specific indication for widespread Barrett’s Esophagus screening using EsoCheck technology.”
     
    Dr. Wurtman received his AB from Harvard College, his medical degree from Harvard Medical School, and his MBA from the MIT Sloan School of Management. Prior to entering the life sciences industry, he completed a primary care internal medicine residency at Mt. Auburn Hospital, a Harvard teaching hospital, and practiced primary care at Harvard Community Health Plan as a board-certified physician in Internal Medicine.
     
    “I am excited to join the PAVmed team and to serve as chief medical officer of Lucid Diagnostics,” said Dr. Wurtman. “Over the past five months I’ve worked closely with the Lucid team to build the vision and operations for our clinical and regulatory strategy to advance EsoCheck. It is my hope that EsoCheck will benefit the tens of millions of patients with GERD who are at risk for Barrett’s Esophagus and esophageal cancer. This ongoing work, in conjunction with the members of our world-class MAB, positions Lucid well to advance EsoCheck successfully through regulatory clearance and potential commercialization.”
     
    EsoCheck is a technology licensed by PAVmed’s majority-owned subsidiary, Lucid Diagnostics Inc., which was highlighted as one of the year’s significant advances in cancer prevention in the National Cancer Institute’s 2020 Annual Plan and Budget Proposal submitted to Congress. It consists of two distinct products. EsoCheck CCD is a balloon catheter designed to collect cells from a targeted region of the esophagus in a five-minute office-based procedure, without the need for endoscopy. EsoCheck Dx is a methylated DNA biomarker test (mVIM + mCCNA1) which has been shown in a published human study to be highly accurate at detecting Barrett’s Esophagus (BE), a pre-cursor to highly lethal esophageal cancer in patients with chronic heart burn or acid reflux (GERD).
     
    The company believes the EsoCheck technology has the potential to save many lives through early BE detection, with an immediately addressable domestic market opportunity of at least $2 billion based on tens of millions U.S. GERD patients who are BE screening candidates based on published guidelines. Lucid is pursuing a two-phase regulatory and commercialization strategy which seeks to maximize the EsoCheck technology’s long-term commercial opportunity while providing near-term value-inflection commercial milestones. The first phase seeks to commercially launch EsoCheck CCD as a U.S. Food and Drug Administration (FDA) 510(k)-cleared cell collection device and separately launch EsoCheck Dx as a Laboratory Developed Test (LDT), which does not currently require FDA review. The second phase seeks a specific indication for widespread BE screening using the two EsoCheck products based on published guidelines.
     
    PAVmed Inc. is a highly differentiated, multiproduct medical device company employing a unique business model designed to advance products to commercialization much more rapidly and with significantly less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation. PAVmed’s pipeline of products address unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its five lead products provide groundbreaking approaches to carpal tunnel syndrome (CarpX), precancerous conditions of the esophagus (EsoCheck), vascular access (PortIO), pediatric ear infections (DisappEAR) and medical infusions (NextFlo). The company is also developing products in other areas, such as catheters and tissue ablation, while seeking to further expand its pipeline through engagements with clinician innovators and leading academic medical centers. 
    Related Searches
    • technology
    • design
    • forward
    • medical
    Suggested For You
    Fist Assist Devices Forms Global Medical Advisory Board Fist Assist Devices Forms Global Medical Advisory Board
    A New, Tailored Review Framework for Artificial Intelligence-Based Devices A New, Tailored Review Framework for Artificial Intelligence-Based Devices
    FDA to Modernize Mammography Services and Improve Their Quality FDA to Modernize Mammography Services and Improve Their Quality
    Medtronic Launches MedTech Innovation Accelerator in Shanghai Medtronic Launches MedTech Innovation Accelerator in Shanghai
    FDA Warns J&J and Sientra for Breast Implant Compliance Failure FDA Warns J&J and Sientra for Breast Implant Compliance Failure
    Candela and InMode Settle Patent Suit Candela and InMode Settle Patent Suit
    FDA to Closely Examine Surgical Stapler Risks FDA to Closely Examine Surgical Stapler Risks
    Vascular Dynamics Names Chief Medical Officer Vascular Dynamics Names Chief Medical Officer
    FDA Commissioner Scott Gottlieb to Step Down FDA Commissioner Scott Gottlieb to Step Down
    Medtronic Enrolls First Patient in Clinical Study to Assess Pain Control and Oral Opioid Elimination Medtronic Enrolls First Patient in Clinical Study to Assess Pain Control and Oral Opioid Elimination
    ICU Medical Recalls ChemoLock Vial Spike (20mm) Due to Risk of Detached Plastic Particles ICU Medical Recalls ChemoLock Vial Spike (20mm) Due to Risk of Detached Plastic Particles
    FDA Orders Doctor to Cease Marketing Unapproved Breast Augmentation Device FDA Orders Doctor to Cease Marketing Unapproved Breast Augmentation Device
    CSA Medical Announces First Patients in Oklahoma Treated with truFreeze Spray Cryotherapy CSA Medical Announces First Patients in Oklahoma Treated with truFreeze Spray Cryotherapy
    Latest Steps to Strengthen FDA’s 510(k) Program for Premarket Review Latest Steps to Strengthen FDA’s 510(k) Program for Premarket Review
    New Skin Test Detects Prion Infection Before Symptoms Appear New Skin Test Detects Prion Infection Before Symptoms Appear

    Related Breaking News

    • Fist Assist Devices Forms Global Medical Advisory Board

      Fist Assist Devices Forms Global Medical Advisory Board

      The board includes renowned leaders in the fields of vascular access and surgery.
      Business Wire 04.04.19

    • Digital Health | Software & IT
      A New, Tailored Review Framework for Artificial Intelligence-Based Devices

      A New, Tailored Review Framework for Artificial Intelligence-Based Devices

      The FDA is exploring a framework that would allow for modifications to algorithms to be made from real-world learning and adaptation.
      Scott Gottlieb, M.D. , Commissioner, U.S. Food and Drug Administration 04.03.19

    • Diagnostics
      FDA to Modernize Mammography Services and Improve Their Quality

      FDA to Modernize Mammography Services and Improve Their Quality

      Proposed rule would require breast density reporting, enhance the FDA’s ability to enforce mammography facilities’ compliance with standards.
      U.S. Food and Drug Administration 03.27.19


    • Medtronic Launches MedTech Innovation Accelerator in Shanghai

      Medtronic Launches MedTech Innovation Accelerator in Shanghai

      Early-stage business accelerator to empower local medtech innovation and enhance Medtronic China's industry leadership.
      Medtronic 03.26.19

    • Surgical
      FDA Warns J&J and Sientra for Breast Implant Compliance Failure

      FDA Warns J&J and Sientra for Breast Implant Compliance Failure

      The two breast implant manufacturers failed to comply with post-approval study requirements.
      U.S. Food and Drug Administration 03.20.19

    Loading, Please Wait..

    Trending
    • Cardinal Health CEO Mike Kaufmann Steps Down
    • Medidata Unveils New Tech To Improve Clinical Trial Oversight
    • How To Overcome The Top 6 Medical Device Manufacturing Challenges
    • TruArc Expands Medical Portfolio With Acquisition Of Molded Devices Inc.
    • Chronic, Infectious Disease Prevalence To Benefit Vital Signs Monitoring Market
    Breaking News
    • BD Recalls Intraosseous Products Over Multiple Issues
    • Rapid Medical Expands U.S. Portfolio
    • MMS Holdings Partners With Lindsay Goldberg
    • ENDRA Life Sciences Issued 28th Patent
    • Levita Magnetics Closes $26M Series C
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • Parylene Coatings for Medical Device Technologies
    • Nearshoring Trends in Medtech Manufacturing
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Charlotte’s Web Sports Product Line to Undergo NSF Certification Process
    ADM and Benson Hill Partner to Scale High Protein Soy for U.S. Market
    Tazo Transitions to Regenerative Organic Agriculture
    Coatings World

    Latest Breaking News From Coatings World

    Valspar Reveals Fresh Lineup of New Shades in 2023 Colors of the Year
    Evonik Grows Strongly in 1H 2022
    PPG Chairman and CEO Joins Disability:IN Effort to Advance Disability Inclusion
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    BD Recalls Intraosseous Products Over Multiple Issues
    Rapid Medical Expands U.S. Portfolio
    MMS Holdings Partners With Lindsay Goldberg
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Almac Invests $65M to Expand North American HQ
    Pace Appoints Nisheet Gupta as EVP and Chief Financial Officer
    West Pharmaceutical Makes Strategic Investment in Latch Medical
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Arkay Chairman Emeritus Howard Kaneff Has Died
    Nutricosmetics Market to Hit $13.7 Billion by 2030
    Estée Lauder Pledges 100% Electric Fleet of Vehicles by 2030
    Happi

    Latest Breaking News From Happi

    Hair Product Patented by L’Oréal
    Murad Unveils Supplement Product Lineup to Combat Acne, Aging
    R+Co Launches New Hairstyling Products
    Ink World

    Latest Breaking News From Ink World

    Evonik Enjoys 31% Growth in 1H 2022
    Sun Chemical Returns to Labelexpo Americas 2022
    DIC Reports Consolidated Financial Results 1H 2022
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Hybrid Software joins The Flexo Xperience Center
    Flexo Wash LLC and Mike Potter celebrate 20 years
    Colordyne hosts open house featuring hybrid print technology
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Focke & Co. to Host Destination: Your Hygiene Hub on August 31
    Exports Dominate Chinese Trade of Tissues, Hygiene Products and Wipes
    Freudenberg to Present Friction Inserts for Wind Energy
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Study Results Released for Abbott's Concussion Blood Test
    Bone Growth Stimulators Market to Top $3B by 2030
    Surgalign, RTI Settle Lawsuit Over OEM Biz Sale
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Zebra Technologies’ Emission Reduction Targets Validated by SBTi
    Identiv Delivers Impressive 41% Year-over-Year Growth in RFID Business
    Stratasys Signs Agreement to Acquire Covestro’s Additive Manufacturing Materials Business

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login